Mon panier

GFR alpha-1

GFR alpha-1 Informations sur la molécule

Nom anglaisGlial cell line-derived neurotrophic factor receptorsNombre de médicaments commercialisés0
Nombre de médicaments cliniques3Alias de la cibleGlial Cell Line-Derived Neurotrophic Factor Receptors
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisGlial cell line-derived neurotrophic factor receptors
Alias de la cibleGlial Cell Line-Derived Neurotrophic Factor Receptors
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques3
Phase de R&D la plus avancéePhase 2 Clinical

GFR alpha-1 Liste de produits

  • Attribut

    Protein (1)

  • Bibliothèque de produits

    En ligne (1)

  • Espèces

    Human (1)

  • Étiquette

    His Tag (1)

  • Marqueur

    Unconjugated (1)

Numéro de produitEspècesSystème d'expressionDescription du produitStructure protéiquePuretéCaractéristiquesPré-commande/Commande
GF1-H5224
Human
HEK293
Human GFR alpha-1 Protein, His Tag
Ajouter au panier
Quantité totale1
  • 1

GFR alpha-1Contexte de la molécule

GDNF family receptor alpha-1 (GFRA1) is also known as RET ligand 1 (RETL1), TGF-beta-related neurotrophic factor receptor 1 (TRNR1), is a novel glycosylphosphatidylinositol (GPI)-linked cell surface receptor, and belongs to the glial cell line-derived neurotrophic factor (GDNF) receptor subfamily. The GDNF family ligands comprises GDNF, Neurturin (NTN), Artemin, and Persephin. GDNF and NTN are two structurally related, potent neurotrophic factors that play key roles in the control of neuron survival and differentiation. GFRA1 mediates the association with and activation of the RET tyrosine kinase receptor (RTK), and subsequently initiates the RET signaling pathway. GFR alpha-mediated signaling plays an important role in the survival, differentiation, and migration of central and peripheral neurons, and is essential for the development of kidneys and the enteric nervous system, as well as the inflammatory response in some carciniomas.

GFR alpha-1Alias de la molécule

GFRA1,GDNFRA,RETL1,TRNR1,GDNFR,GFR-ALPHA-1,RET1L

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
KLS-2031KLS-2031Phase 2 ClinicalKolon Life Science. IncNeuralgia; Radiculopathy
Details
NGM-386NGM-386Phase 1 ClinicalNGM Biopharmaceuticals IncObesity
Details
NGM-395NGM-395Phase 1 ClinicalNGM Biopharmaceuticals IncMetabolic Dysfunction-Associated Steatotic Liver Disease; Obesity
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments cliniques